Is the clinical efficacy of tolterodine extended-release maintained for 24 h in patients with overactive bladder?
These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.
Antibodies to GM-CSF and IL3 are rare in patients with FS and RA and in healthy subjects. In individual patients with FS, the presence of neutralising anti-IL3 antibodies may contribute to the development of cytopenia.